Study the effect of obesity on levels of plasminogen activator inhibitor-1 and adiponectin as a pre-diagnosis for cardiovascular disease

Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure and coronary heart disease (CHD). It directly contributes to cardiovascular risk factors, including obesity, dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. In this study, it was aimed to investigate the effect of obesity on plasminogen activator-inhibitor-1 and adiponectin levels as a preliminary diagnosis of cardiovascular disease. The study was carried out in Imam Hussain Training Hospital in Zi-kar city, Iraq, by forming a patient and control group, and 50 patients in each group, aged between 35-45, with a total of 100 people. Blood samples were taken from all individuals for serum research. Serum cholesterol, serum triglyceride, serum low-density lipoprotein (LDL), serum high-density lipoprotein (HDL), serum very low-density lipoprotein (VLDL), serum triglyceride, serum plasminogen activator inhibitor-1 and serum adiponectin levels were measured in blood serum samples. When the first and second groups are compared, the differences between the two groups are statistically significant. The results showed that plasminogen activator inhibitor-1 levels were significantly higher in patients with obesity compared to the control group. Mean serum adiponectin values were significantly lower in the obese patient group compared to controls. On the basis of all results, it was concluded that overweight and obesity have strong risk factors for the development of cardiovascular disease, such as heart failure and coronary heart disease. Keywords: Obesity, Cardiovascular Disease, Plasminogen Activator Inhibitor-1, Adiponectin, Lipid Profile